SCHEMBL1592286

SCHEMBL1592286

CC1(C)[C@@H]2[C@@H](C(=O)O)NC[C@@H]21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.43
SLC1A2 P43004 6/20 0.42
CYP1A2 P05177 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SLC1A1 P43005 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ALOX15 P16050 3/20 0.38
MAPK1 P28482 1/20 0.37
TSHR P16473 1/20 0.37
THPO P40225 1/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
GRIK1 P39086 1/20 0.37
GRM5 P41594 1/20 0.37
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37
GRIA3 P42263 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16326618 1.00 PKM (0.43) PKMSLC1A2CYP1A2ALDH1A1CYP2C19
SCHEMBL31289285 1.00 PKM (0.43) PKMSLC1A2CYP1A2ALDH1A1CYP2C19
SCHEMBL27788944 1.00 PKM (0.43) PKMSLC1A2CYP1A2ALDH1A1CYP2C19
SCHEMBL1592240 1.00 PKM (0.43) PKMSLC1A2CYP1A2ALDH1A1CYP2C19
SCHEMBL28063284 1.00 PKM (0.43) PKMSLC1A2CYP1A2ALDH1A1CYP2C19
Hydrochloric Acid SCHEMBL25225659 0.98 PKM (0.42) PKMSLC1A2CYP1A2ALDH1A1CYP2C19
Hydrochloric Acid SCHEMBL4300372 0.98 PKM (0.42) PKMSLC1A2CYP1A2ALDH1A1CYP2C19
SCHEMBL28732867 0.98 PKM (0.42) PKMSLC1A2CYP1A2ALDH1A1CYP2C19
Lithium SCHEMBL29718901 0.98 PKM (0.42) PKMSLC1A2CYP1A2ALDH1A1CYP2C19
SCHEMBL30703914 0.98 PKM (0.42) PKMSLC1A2CYP1A2ALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114605310-B Synthesis method of aza five-membered ring and three-membered ring carboxylic ester derivative and salt thereof 都创(上海)医药科技股份有限公司 2024-05-07 CN claimed
CN-114539125-B Synthesis method of paciclovir intermediate 杭州国瑞生物科技有限公司 2024-02-09 CN claimed
WO-2023168827-A1 SYNTHESIS METHOD FOR PAXLOVID INTERMEDIATE 杭州国瑞生物科技有限公司 2023-09-14 WO claimed
WO-2023151188-A1 GREEN SYNTHESIS METHOD OF ANTIVIRAL DRUG INTERMEDIATE 上海皓元医药股份有限公司 2023-08-17 WO claimed
CN-114394927-B Process for the preparation of 6, 6-dimethyl-3-azabicyclo [3.1.0] hexane-2-carboxylic acid 汉瑞药业(荆门)有限公司 2023-03-31 CN claimed
CN-115109760-A Monoamine oxidase and application thereof in preparation of pharmaceutical intermediate 弈柯莱生物科技(上海)股份有限公司 2022-09-27 CN claimed
CN-114958938-A Preparation method of fused bicyclic proline methyl ester hydrochloride 金达威生物技术(江苏)有限公司 2022-08-30 CN claimed
CN-114671798-B Green synthesis method of antiviral drug intermediate 上海皓元医药股份有限公司 2022-08-16 CN claimed
CN-114671798-A Green synthesis method of antiviral drug intermediate 上海皓元医药股份有限公司 2022-06-28 CN claimed
CN-114605310-A Synthesis method of aza five-membered ring and three-membered ring carboxylate derivative and salt thereof 都创(上海)医药科技股份有限公司 2022-06-10 CN claimed
CN-114539125-A Synthetic method of pasiclovir intermediate 杭州国瑞生物科技有限公司 2022-05-27 CN claimed
CN-114456101-A Synthesis method of key intermediate for synthesizing PF-07321332 上海璨谊生物科技有限公司 2022-05-10 CN claimed
CN-114394927-A Process for preparing 6, 6-dimethyl-3-azabicyclo [3.1.0] hexane-2-carboxylic acid 汉瑞药业(荆门)有限公司 2022-04-26 CN claimed
CN-114031543-A Preparation method of intermediate of palovaried 上海朴颐化学科技有限公司 2022-02-11 CN claimed
US-12365706-B2 Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant MERCK SHARP & DOHME LLC (US) 2025-07-22 US disclosed
CN-119677728-A Process and intermediates for the preparation of nemaltevir 辉瑞大药厂 2025-03-21 CN disclosed
US-20250059171-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-02-20 US disclosed
CN-1805931-A Processes and intermediates for preparing (1R,2S,5S) -6, 6-dimethyl-3-azabicyclo [3,1,0] hexane-2-carboxylate or salts thereof SCHERING CORP (US) 2006-07-19 CN disclosed
US-20050059648-A1 Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof SCHERING CORPORATION 2005-03-17 US disclosed
US-20050059648-A1 Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof SCHERING CORPORATION 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12365706-B2 Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant KRAS, NRAS, HRAS PKM 2452/4885SLC1A2 4343/4885CYP1A2 4508/4885
US-20050059648-A1 Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof AZI2, MED1, ALKBH5 PKM 2170/4885SLC1A2 4152/4885CYP1A2 104/4885
US-20250059171-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, ACE, EIF2AK2 PKM 1850/4885SLC1A2 4727/4885CYP1A2 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.